Literature DB >> 759616

Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat.

J T Lettieri, H L Fung.   

Abstract

The pharmacokinetics of sodium-gamma-hydroxybutyrate (NaGHB) have been examined as functions of dose and route of administration. The elimination of NaGHB appeared to be controlled by a capacity-limited process which can be described by Michaelis-Menten kinetics. Oral absorption of NaGHB appeared to be fairly extensive in the dose range studied (200-1600 mg/kg), but the peak drug plasma concentrations achieved after oral dosing were relatively low and insensitive to changes in the magnitude of the dose, explaining the lack of pharmacological activity, viz., hypnosis, after oral NaGHB administration even at comparatively high doses. Plasma and brain concentrations were determined at the time when the animals recovered from the hypnotic effects of NaGHB. These concentrations also appeared to be dose-dependent, although the ratio of "waking" plasma to brain concentration was constant with respect to dose.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759616

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

1.  Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.

Authors:  Indranil Bhattacharya; Kathleen M K Boje
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-08-29       Impact factor: 2.745

2.  An interactive lesson in acid/base and pro-drug chemistry using sodium gamma-hydroxybutyrate and commercial test coasters.

Authors:  Nathaniel A Page; Meaghan Paganelli; Kathleen M K Boje; Ho-Leung Fung
Journal:  Am J Pharm Educ       Date:  2007-06-15       Impact factor: 2.047

3.  Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate.

Authors:  Bridget L Morse; Nisha Vijay; Marilyn E Morris
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

4.  Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats.

Authors:  Samuel A Roiko; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-21       Impact factor: 3.922

5.  Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome.

Authors:  Todd J Swick
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

6.  Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.

Authors:  Marilyn E Morris; Bridget L Morse; Gloria J Baciewicz; Matthew M Tessena; Nicole M Acquisto; David J Hutchinson; Robert Dicenzo
Journal:  J Clin Toxicol       Date:  2011-11-10

7.  Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.

Authors:  P Palatini; L Tedeschi; G Frison; R Padrini; R Zordan; R Orlando; L Gallimberti; G L Gessa; S D Ferrara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Authors:  Nisha Vijay; Bridget L Morse; Marilyn E Morris
Journal:  Pharm Res       Date:  2014-12-06       Impact factor: 4.200

9.  Monocarboxylate transporter-mediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells.

Authors:  Wing Ki Lam; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2009-12-01       Impact factor: 3.922

10.  Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses.

Authors:  S D Ferrara; S Zotti; L Tedeschi; G Frison; F Castagna; L Gallimberti; G L Gessa; P Palatini
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.